Mucosal vaccination: Opportunities and challenges

Novel Immune Potentiators and Delivery Technologies for Next Generation Vaccines

Volumn , Issue , 2013, Pages 65-80

  Borges, Olga ^a   Borchard, Gerrit ^a  

^a UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84903433993     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-5380-2_3     Document Type: Chapter

References (75)

1. Goldsby RA (2003) Immunology, 5th edn. W.H. Freeman, New York
2. Holmgren J, Czerkinsky C (2005) Mucosal immunity and vaccines. Nat Med 11(suppl 4):S45-S53
3. Czerkinsky C, Prince SJ, Michalek SM, Jackson S, Russell MW, Moldoveanu Z et al (1987) IgA antibody-producing cells in peripheral blood after antigen ingestion: evidence for a common mucosal immune system in humans. Proc Natl Acad Sci USA 84(8):2449-2453
4. McDermott MR, Bienenstock J (1979) Evidence for a common mucosal immunologic system. I. Migration of B immunoblasts into intestinal, respiratory, and genital tissues. J Immunol 122(5):1892-1898
5. Kiyono H, Fukuyama S (2004) NALT- versus Peyer's-patch-mediated mucosal immunity. Nat Rev Immunol 4(9):699-710
6. Clark MA, Jepson MA, Hirst BH (2001) Exploiting M cells for drug and vaccine delivery. Adv Drug Deliv Rev 50(1-2):81-106
7. Kuper CF, Koornstra PJ, Hameleers DM, Biewenga J, Spit BJ, Duijvestijn AM et al (1992) The role of nasopharyngeal lymphoid tissue. Immunol Today 13(6):219-224
8. Davis SS (2001) Nasal vaccines. Adv Drug Deliv Rev 51(1-3):21-42
9. Illum L, Davis SS (2001) Nasal vaccination: a non-invasive vaccine delivery method that holds great promise for the future. Adv Drug Deliv Rev 51(1-3):1-3
10. Vajdy M, Baudner B, Del Giudice G, O'Hagan D (2007) A vaccination strategy to enhance mucosal and systemic antibody and T cell responses against influenza. Clin Immunol 123(2):166-175
11. Porgador A, Staats HF, Itoh Y, Kelsall BL (1998) Intranasal immunization with cytotoxic T-lymphocyte epitope peptide and mucosal adjuvant cholera toxin: selective augmentation of peptide-presenting dendritic cells in nasal mucosa-associated lymphoid tissue. Infect Immun 66(12):5876-5881
12. Shreedhar VK, Kelsall BL, Neutra MR (2003) Cholera toxin induces migration of dendritic cells from the subepithelial dome region to T- and B-cell areas of Peyer's patches. Infect Immun 71(1):504-509
13. Mowat AM (2003) Anatomical basis of tolerance and immunity to intestinal antigens. Nat Rev Immunol 3(4):331-341
14. Neutra MR, Kozlowski PA (2006) Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 6(2):148-158
15. Gewirtz AT, Madara JL (2001) Periscope, up! Monitoring microbes in the intestine. Nat Immunol 2(4):288-290
16. Shikina T, Hiroi T, Iwatani K, Jang MH, Fukuyama S, Tamura M et al (2004) IgA class switch occurs in the organized nasopharynx- and gut-associated lymphoid tissue, but not in the diffuse lamina propria of airways and gut. J Immunol 172(10):6259-6264
17. Kunkel EJ, Butcher EC (2003) Plasma-cell homing. Nat Rev Immunol 3(10):822-829
18. Baudner BC, Morandi M, Giuliani MM, Verhoef JC, Junginger HE, Costantino P et al (2004) Modulation of immune response to group C meningococcal conjugate vaccine given intranasally to mice together with the LTK63 mucosal adjuvant and the trimethyl chitosan delivery system. J Infect Dis 189(5):828-832
19. Lamm ME (1997) Interaction of antigens and antibodies at mucosal surfaces. Annu Rev Microbiol 51:311-340
20. Hutchings AB, Helander A, Silvey KJ, Chandran K, Lucas WT, Nibert ML et al (2004) Secretory immunoglobulin A antibodies against the sigma1 outer capsid protein of reovirus type 1 Lang prevent infection of mouse Peyer's patches. J Virol 78(2):947-957
21. Mayer L, Shao L (2004) Therapeutic potential of oral tolerance. Nat Rev Immunol 4(6):407-419
22. Sansonetti PJ, Medzhitov R (2009) Learning tolerance whilefighting ignorance. Cell 138(3):416-420
23. Woodley JF (1994) Enzymatic barriers for GI peptide and protein delivery. Crit Rev Ther Drug Carrier Syst 11(2-3):61-95
24. Tsukita S, Furuse M, Itoh M (2001) Multifunctional strands in tight junctions. Nat Rev Mol Cell Biol 2(4):285-293
25. Engel J, Eran Y (2011) Subversion of mucosal barrier polarity by pseudomonas aeruginosa. Front Microbiol 2:114
26. Rescigno M, Urbano M, Valzasina B, Francolini M, Rotta G, Bonasio R et al (2001) Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat Immunol 2(4):361-367
27. Borchard G, Junginger HE (2001) Modern drug delivery applications of chitosan. Adv Drug Deliv Rev 52(2):103
28. Olmsted SS, Padgett JL, Yudin AI, Whaley KJ, Moench TR, Cone RA (2001) Diffusion of macromolecules and virus-like particles in human cervical mucus. Biophys J 81(4):1930-1937
29. McGuckin MA, Linden SK, Sutton P, Florin TH (2011) Mucin dynamics and enteric pathogens. Nat Rev Microbiol 9(4):265-278
30. Hattrup CL, Gendler SJ (2008) Structure and function of the cell surface (tethered) mucins. Annu Rev Physiol 70:431-457
31. Marchiando AM, Graham WV, Turner JR (2010) Epithelial barriers in homeostasis and disease. Annu Rev Pathol 5:119-144
32. Atuma C, Strugala V, Allen A, Holm L (2001) The adherent gastrointestinal mucus gel layer: thickness and physical state in vivo. Am J Physiol Gastrointest Liver Physiol 280(5):G922-G929
33. Kagnoff MF, Eckmann L (1997) Epithelial cells as sensors for microbial infection. J Clin Invest 100(1):6-10
34. Macpherson AJ, Harris NL (2004) Interactions between commensal intestinal bacteria and the immune system. Nat Rev Immunol 4(6):478-485
35. Nagler-Anderson C, Shi HN (2001) Peripheral nonresponsiveness to orally administered soluble protein antigens. Crit Rev Immunol 21(1-3):121-131
36. Nagler-Anderson C (2001) Man the barrier! Strategic defences in the intestinal mucosa. Nat Rev Immunol 1(1):59-67
37. Sansonetti PJ (2011) To be or not to be a pathogen: that is the mucosally relevant question. Mucosal Immunol 4(1):8-14
38. Viney JL, Mowat AM, O'Malley JM, Williamson E, Fanger NA (1998) Expanding dendritic cells in vivo enhances the induction of oral tolerance. J Immunol 160(12):5815-5825
39. Scheinecker C, McHugh R, Shevach EM, Germain RN (2002) Constitutive presentation of a natural tissue autoantigen exclusively by dendritic cells in the draining lymph node. J Exp Med 196(8):1079-1090
40. Kunkel D, Kirchhoff D, Nishikawa S, Radbruch A, Scheffold A (2003) Visualization of peptide presentation following oral application of antigen in normal and Peyer's patchesde ficient mice. Eur J Immunol 33(5):1292-1301
41. Spahn TW, Fontana A, Faria AM, Slavin AJ, Eugster HP, Zhang X et al (2001) Induction of oral tolerance to cellular immune responses in the absence of Peyer's patches. Eur J Immunol 31(4):1278-1287
42. Mebius RE, Kraal G (2005) Structure and function of the spleen. Nat Rev Immunol 5(8):606-616
43. Stertman L, Lundgren E, Sjoholm I (2006) Starch microparticles as a vaccine adjuvant: only uptake in Peyer's patches decides the profile of the immune response. Vaccine 24(17):3661-3668
44. Borges O, Lebre F, Bento D, Borchard G, Junginger HE (2010) Mucosal vaccines: recent progress in understanding the natural barriers. Pharm Res 27(2):211-223
45. Zuo YY, Alolabi H, Shafiei A, Kang N, Policova Z, Cox PN et al (2006) Chitosan enhances the in vitro surface activity of dilute lung surfactant preparations and resists albumin-induced inactivation. Pediatr Res 60(2):125-130
46. O'Hagan D (2006) Microparticles as vaccine delivery systems. In: Schijins V, O'Hagan D (eds) Immunopotentiators in modern vaccines, 1st edn. Academic, Burlington, pp 123-147
47. Dupuis M, Denis-Mize K, LaBarbara A, Peters W, Charo IF, McDonald DM et al (2001) Immunization with the adjuvant MF59 induces macrophage trafficking and apoptosis. Eur J Immunol 31(10):2910-2918
48. van der Lubben IM, Kersten G, Fretz MM, Beuvery C, Coos Verhoef J, Junginger HE (2003) Chitosan microparticles for mucosal vaccination against diphtheria: oral and nasal efficacy studies in mice. Vaccine 21(13-14):1400-1408
49. Pearse MJ, Drane D (2005) ISCOMATRIX adjuvant for antigen delivery. Adv Drug Deliv Rev 57(3):465-474
50. Florindo HF, Pandit S, Goncalves LM, Alpar HO, Almeida AJ (2008) Streptococcus equi antigens adsorbed onto surface modified poly-epsilon-caprolactone microspheres induce humoral and cellular specific immune responses. Vaccine 26(33):4168-4177
51. O'Hagan DT (1998) Microparticles and polymers for the mucosal delivery of vaccines. Adv Drug Deliv Rev 34(2-3):305-320
52. O'Hagan DT, Singh M (2003) Microparticles as vaccine adjuvants and delivery systems. Expert Rev Vaccines 2(2):269-283
53. O'Hagan DT, Singh M, Ulmer JB (2004) Microparticles for the delivery of DNA vaccines. Immunol Rev 199:191-200
54. Storni T, Kundig TM, Senti G, Johansen P (2005) Immunity in response to particulate antigendelivery systems. Adv Drug Deliv Rev 57(3):333-355
55. Tamber H, Johansen P, Merkle HP, Gander B (2005) Formulation aspects of biodegradable polymeric microspheres for antigen delivery. Adv Drug Deliv Rev 57(3):357-376
56. Jilek S, Merkle HP, Walter E (2005) DNA-loaded biodegradable microparticles as vaccine delivery systems and their interaction with dendritic cells. Adv Drug Deliv Rev 57(3):377-390
57. Waeckerle-Men Y, Groettrup M (2005) PLGA microspheres for improved antigen delivery to dendritic cells as cellular vaccines. Adv Drug Deliv Rev 57(3):475-482
58. Florence AT (1997) The oral absorption of micro- and nanoparticulates: neither exceptional nor unusual. Pharm Res 14(3):259-266
59. Hussain N, Jaitley V, Florence AT (2001) Recent advances in the understanding of uptake of microparticulates across the gastrointestinal lymphatics. Adv Drug Deliv Rev 50(1-2):107-142
60. Jung T, Kamm W, Breitenbach A, Kaiserling E, Xiao JX, Kissel T (2000) Biodegradable nanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosal uptake? Eur J Pharm Biopharm 50(1):147-160
61. Cano-Cebrian MJ, Zornoza T, Granero L, Polache A (2005) Intestinal absorption enhancement via the paracellular route by fatty acids, chitosans and others: a target for drug delivery. Curr Drug Deliv 2(1):9-22
62. Aprahamian M, Michel C, Humbert W, Devissaguet JP, Damge C (1987) Transmucosal passage of polyalkylcyanoacrylate nanocapsules as a new drug carrier in the small intestine. Biol Cell 61(1-2):69-76
63. MacDonald TT (2003) The mucosal immune system. Parasite Immunol 25(5):235-246
64. Jabbal-Gill I, Lin W, Jenkins P, Watts P, Jimenez M, Illum L et al (1999) Potential of polymeric lamellar substrate particles (PLSP) as adjuvants for vaccines. Vaccine 18(3-4):238-250
65. Holmgren J, Harandi A, Lebens M, Sun J-B, Anjuère F, Czerkinsky C (2006) Mucosal adjuvants based on cholera toxin and E. coli heat-labile enterotoxin. In: Schijns V, O'Hagan D (eds) Immunopotentiators in modern vaccines, 1st edn. Academic, Burlington, pp 235-252
66. Douce G, Fontana M, Pizza M, Rappuoli R, Dougan G (1997) Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin. Infect Immun 65(7):2821-2828
67. Douce G, Turcotte C, Cropley I, Roberts M, Pizza M, Domenghini M et al (1995) Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants. Proc Natl Acad Sci USA 92(5):1644-1648
68. Fujihashi K, Koga T, van Ginkel FW, Hagiwara Y, McGhee JR (2002) A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants. Vaccine 20(19-20):2431-2438
69. Levine MM (2000) Immunization against bacterial diseases of the intestine. J Pediatr Gastroenterol Nutr 31(4):336-355
70. Malkevitch NV, Robert-Guroff M (2004) A call for replicating vector prime-protein boost strategies in HIV vaccine design. Expert Rev Vaccines 3(suppl 4):S105-S117
71. Cox E, Verdonck F, Vanrompay D, Goddeeris B (2006) Adjuvants modulating mucosal immune responses or directing systemic responses towards the mucosa. Vet Res 37(3):511-539
72. O'Hagan DT, Valiante NM (2003) Recent advances in the discovery and delivery of vaccine adjuvants. Nat Rev Drug Discov 2(9):727-735
73. McCluskie MJ, Weeratna RD (2006) CpG oligodeoxynucleotides as vaccine adjuvants. In: Schijins V, O'Hagan D (eds) Immunopotentiators in modern vaccines, 1st edn. Academic, Burlington, pp 73-92
74. McSorley SJ, Ehst BD, Yu Y, Gewirtz AT (2002) Bacterialflagellin is an effective adjuvant for CD4+ T cells in vivo. J Immunol 169(7):3914-3919
75. Chabot S, Brewer A, Lowell G, Plante M, Cyr S, Burt DS et al (2005) A novel intranasal Protollin-based measles vaccine induces mucosal and systemic neutralizing antibody responses and cell-mediated immunity in mice. Vaccine 23(11):1374-1383